Ihuman Inc
Change company Symbol lookup
Select an option...
IH Ihuman Inc
LMT Lockheed Martin Corp
GBRGU Goldenbridge Acquisition Ltd
GBLX GB Sciences Inc
AROC Archrock Inc
AAPL Apple Inc
PCTY Paylocity Holding Corp
CPNG Coupang Inc
GVHIB Global Vision Holdings Inc
TREX Trex Company Inc
Go

Communication Services : Entertainment |
Based in China
Company profile

iHuman Inc is a China-based company engaged in providing education services and products for kids. The Company mainly provides learning services for 3-8 years old children under its brand iHuman, such as iHuman Chinese, iHuman English World, iHuman Pinyin, iHuman Magic Math and other learning applications. The Company also provides learning materials and devices to individual users, education organizations and third-party distributors. The learning materials cover literacy and reading, English, mathematics, music and other subjects.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$3.90
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
16,306
0

SESN 5-DAY DEADLINE ALERT: Hagens Berman Encourages Sesen Bio (SESN) Investors with Significant Losses to Contact Firm's Attorneys Now, OCT. 18TH LEAD PLAINTIFF DEADLINE in Securities Class Action

3:21 pm ET October 13, 2021 (Accesswire) Print

SAN FRANCISCO, CA / ACCESSWIRE / October 13, 2021 / Hagens Berman urges Sesen Bio, Inc. (NASDAQ:SESN) investors with losses in excess of $250,000 to submit your losses now.

Class Period: Dec. 21, 2020 - Aug. 17, 2021

Lead Plaintiff Deadline: Oct. 18, 2021

Visit: www.hbsslaw.com/investor-fraud/SESN

Contact An Attorney Now: SESN@hbsslaw.com

844-916-0895

Sesen Bio, Inc. (SESN) Securities Fraud Class Action:

The complaint alleges that Defendants misrepresented clinical trial data for Sesen's lead product candidate Vicineum for the treatment of certain non-muscle invasive bladder cancer.

Specifically, Defendants concealed that: (1) the company's clinical trial for Vicineum had more than 2,000 protocol violations, including 215 classified as "major," (2) three of the company's clinical investigators were found guilty of "serious noncompliance," including backdating data, (3) the company submitted tainted data for Vicineum to the FDA, (4) the company's clinical trials showed that Vicineum leaked out into the body and caused serious side effects and increased risks for fatal liver injury.

The truth began to emerge on Aug. 13, 2021, when Sesen announced the FDA did not approve the BLA in its present form and sought additional clinical/statistical data.

Then, on Aug. 16, 2021, the company revealed it needed to conduct an additional clinical trial to provide the FDA with additional efficacy and safety data.

Finally, on Aug. 18, 2021, STAT published an article entitled "Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show." STAT cited hundreds of pages of internal documents and three people familiar with the matter reported the Vicineum clinical trial "was marked by thousands of violations of study rules, damning investigator conduct, and worrying signs of toxicity the company did not publicly disclose."

These events sent the price of Sesen shares sharply lower.

"We're focused on investors' losses and proving Sesen lied to them about the prospects for Vicineum," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Sesen and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Sesen should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SESN@hbsslaw.com.

# # #

About Hagens BermanHagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

CONTACT:Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

View source version on accesswire.com: https://www.accesswire.com/667971/SESN-5-DAY-DEADLINE-ALERT-Hagens-Berman-Encourages-Sesen-Bio-SESN-Investors-with-Significant-Losses-to-Contact-Firms-Attorneys-Now-OCT-18TH-LEAD-PLAINTIFF-DEADLINE-in-Securities-Class-Action

comtex tracking

COMTEX_395127046/2457/2021-10-13T15:21:49

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.